This invention combines the microfluidic and microelectronic devices and techniques required for the microminiaturization of cell culture and cell measurement systems to allow monitoring the response of populations of 1 to several hundred living cells. The instrument(s) allows for the detection of extracellular, membrane, and intracellular parameters; and the incorporation of closed-loop control techniques to continuously monitor the health of the cell and adjust the environmental and pharmacological parameters that control the cell.
REDCap (Research Electronic Data Capture) is a secure web application for building and managing online surveys and databases. Despite its broad potential application, the primary function is for Electronic Data Capture, specifi cally for Clinical Trial Management solutions. REDCap is a globally implemented platform at more than 906 institutional partners from CTSA, GCRC, RCMI and other institutions in 73 countries. The REDCap application allows users to build and manage online surveys and databases quickly and securely, and is currently in production use or development build-status for more than 92,000 projects with over 119,000 users spanning numerous research focus areas across the consortium.
The invention is a device which permits the direct quantification of leachable organic constituents from within solid materials. It is expected that the device will be used in landfills and in other environments where measurements are central to the evaluation of the environmental compatibility of solid materials (e.g., sediments, soils, solidified waste forms) containing organic constituents that have the potential to degrade water resources of to be taken up by biota and the food chain. The invention is designed to simplify current difficulties in assessing leaching of organic constituents with low aqueous solubility.
Commercial routes to industrially important pharmaceutical and agrichemical compounds can often be developed more economically when separation of enantiomeric intermediates/ products is possible. Vanderbilt University seeks to license technologies, originally invented at DuPont, that allow such separations to be performed via novel biocatalysts. Vanderbilt's technology can be used for the production of chiral tertiary esters and/ or enantiomeric amides. In the case of the former class of compounds, our technology is somewhat unique in its ability to operate on carbonyl groups alpha to a tertiary center. See the following description for more information about the current status of this technology and the associated patent estate.
It is estimated that approximately 30% of men have reduced fertility and 2% are totally infertile. Despite these large numbers relatively little is know about the molecular bases of male infertility. On the flip side of male infertility is the need for male contraception. Currently there are no reversible, convenient male contraceptives available. In order to develop male contraceptives and acquire a greater understanding of male fertility there is a need to develop animal models to study the molecular basis and pathways that regulate and control male fertility. Vanderbilt researchers have developed a model mouse system to study male fertility. There research focuses on the epididymus, which is the area that spermatozoa acquire the ability to move and fertilize. For this region to be functional tissue and cell specific gene regulation must occur. These investigators have discovered one such gene regulated within this area, mEP17. These researchers can fuse either mouse or human EP17 or just the regulatory regions of either EP17 to reporter genes and the resulting fusion can be used to screen for substances that regulate this gene and affect male fertility. This system becomes a powerful tool to identify drugs which affect this gene and be potential male contraceptives. In addition polypeptides generated to this gene may be used as vaccines for male contraceptives.